Iomai news from FierceBiotech
News
Intercell snaps up Iomai in $189M deal
The little Maryland-based vaccine developer Iomai, which has posted some impressive data on a new therapy for Read more...
Feds ok Iomai Phase II adjuvant patch study
Health and Human Services is giving Iomai the green light to do a mid-stage dose ranging study of its adjuvant patch for bird flu vaccine. HHS provided a $128 million contract backing Iomai's effort Read more...
ALSO NOTED: Dendreon shares jump on investment deal; Iomai in pact with Merck; Foundation antes millions for MS leads; and much
> Schering-Plough has proven quick on the layoff trigger. The company announced a plan to cut costs by $1.5 billion by 2012 in the wake of the latest round of Vytorin controversy. Roughly 5,500 Read more...
Emerging Drug Developer: Iomai
Little Iomai comes up with a potentially big hit for bird flu In the scramble to come up with new vaccines that could protect populations from a potential human outbreak, scientists have frequently Read more...
Get more Iomai coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends